Welcome to LookChem.com Sign In|Join Free
  • or
3,7-Dihydro-5,6-dimethyl-4H-pyrrolo[2,3-d]pyrimidin-4-one is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

82703-35-3

Post Buying Request

82703-35-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

82703-35-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 82703-35-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,7,0 and 3 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 82703-35:
(7*8)+(6*2)+(5*7)+(4*0)+(3*3)+(2*3)+(1*5)=123
123 % 10 = 3
So 82703-35-3 is a valid CAS Registry Number.

82703-35-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 5,6-dimethyl-1,7-dihydropyrrolo[2,3-d]pyrimidin-4-one

1.2 Other means of identification

Product number -
Other names 5,6-Dimethyl-7H-pyrrolo<2,3-d>pyrimidin-4(3H)-on

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:82703-35-3 SDS

82703-35-3Downstream Products

82703-35-3Relevant academic research and scientific papers

4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER

-

Paragraph 0105; 0195; 0197, (2021/12/07)

The present invention concerns a compound of formula (I), in particular as LIMK and/or ROCK kinases inhibitors. The present invention also concerns these new inhibitors for use for the treatment of a condition selected in the group consisting of: cancers, virion infections, ocular hypertension and glaucoma formation, Neurofibromatosis type 1 and 2, psoriatic lesions, inflammatory diseases and hyperalgesia, central sensitization and chronic pain, reproduction erectile dysfunction, and neuronal diseases. The present description discloses the syntheses and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 32 to 127; examples 1 to 96; families 1 to 8; compounds; biological studies; tables). An exemplary compound is e.g. 4-(5-m ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-phenyl-3,6-dihydropyridine-1-(2H)-carboxamide (example 1; compound 5).

Synthesis of 7-Unsubstituted 7H-Pyrrolopyrimidines

Pichler, Herbert,Folkers, Gerd,Roth, Hermann J.,Eger, Kurt

, p. 1485 - 1505 (2007/10/02)

The title compounds 4 are obtained by N-7 dealkylation of the 2-furanylmethyl, 2-thiophenylmethyl, or 1-phenylethyl group from 2a-g and 10 a-j with polyphosphoric acid.In contrast to the 2-furanylmethyl group the 2-thiophenylmethyl and 1-phenylethyl group

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 82703-35-3